A Retrospective Chart Review Study of Patients With Chronic Lung Allograft Dysfunction-Bronchiolitis Obliterans Syndrome (CLAD-BOS) Post Lung Transplantation
- Conditions
- Bronchiolitis Obliterans Syndrome Due to and After Lung Transplantation (Disorder)
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Zambon SpA
- Target Recruit Count
- 300
- Registration Number
- NCT06503770
- Locations
- 🇺🇸
Baylor Scott and White Health Advanced Lung Disease Specialists, Dallas, Texas, United States
🇧🇪Universitaire Ziekenhuizen Leuven (UZ Leuven) Campus Gasthuisberg, Leuven, Belgium
🇪🇸Universidad de Cantabria (UC) Hospital Universitario Marques de Valdecilla (HUMV), Santander, Cantabria, Spain
Phase 1 Three Part SAD, MAD & Cross-Over Study of ZP-059 in Healthy and Asthmatic Subjects
- Conditions
- Allergic Bronchopulmonary Aspergillosis
- Interventions
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2021-11-15
- Lead Sponsor
- Zambon SpA
- Target Recruit Count
- 58
- Registration Number
- NCT04229303
- Locations
- 🇬🇧
Medicines Evaluation Unit Ltd. (MEU), Manchester, United Kingdom
A Safety Study of Liposomal Cyclosporine A to Treat Bronchiolitis After Hematopoietic Transplant (BOSTON-4)
- Conditions
- Bronchiolitis Obliterans Syndrome (BOS)Stem Cell Transplant ComplicationsGVHD, Chronic
- Interventions
- Drug: Liposomal Cyclosporine ADrug: Liposomal Placebo
- First Posted Date
- 2019-09-27
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Zambon SpA
- Target Recruit Count
- 6
- Registration Number
- NCT04107675
- Locations
- 🇫🇷
CHU de Nancy, Hopital Brabois, Nancy, France
🇫🇷Centre Hospitalier Universitaire d'Angers, Angers, France
🇫🇷Centre Hospitalier Universitaire Grenoble Alpes - Hopital Albert Michallon, La Tronche, France
Extension Trial on Efficacy / Safety of L-CsA + SoC in Treating BOS in Post Single or Double Lung Transplant (BOSTON-3)
- Conditions
- Bronchiolitis ObliteransObliterative BronchiolitisBronchiolitis Obliterans Syndrome
- Interventions
- Drug: Liposomal Cyclosporine A 5 mgDrug: Liposomal Cyclosporine A 10 mg
- First Posted Date
- 2019-07-31
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Zambon SpA
- Target Recruit Count
- 262
- Registration Number
- NCT04039347
- Locations
- 🇺🇸
Baylor University Medical Center, Dallas, Texas, United States
🇺🇸Banner - University Medical Center, Phoenix, Arizona, United States
🇺🇸Johns Hopkins University Hospital, Baltimore, Maryland, United States
An Observational Study on Safinamide, Rasagiline and Other Standard of Care in PD
- Conditions
- Parkinson's Disease
- First Posted Date
- 2019-06-21
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Zambon SpA
- Target Recruit Count
- 1235
- Registration Number
- NCT03994328
- Locations
- 🇮🇹
Università degli Studi G. D'Annunzio, Chieti, Italy
🇩🇪Praxis Dr. med. Kirsten Hahn, Berlin, Germany
🇪🇸Corporacio Sanitaria Parc Tauli, Sabadell, Spain
Safinamide for Levodopa-induced Dyskinesia (PD-LID)
- Conditions
- Dyskinesia, Drug-InducedParkinson Disease
- Interventions
- First Posted Date
- 2019-06-17
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- Zambon SpA
- Registration Number
- NCT03987750
A Single and Multiple Dose Study to Assess How the Drug Enters, Moves Through and Exits the Body, Safety and Tolerability of Safinamide in Healthy Adult Chinese Volunteers
- First Posted Date
- 2019-03-22
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- Zambon SpA
- Target Recruit Count
- 24
- Registration Number
- NCT03887221
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Med, Shanghai, Shanghai, China
A Study to Evaluate Pharmacokinetics, Safety and Tolerability of Single and Multiple Intravenous Doses of N-acetylcysteine (NAC) in Chinese Healthy Volunteers
- First Posted Date
- 2019-03-19
- Last Posted Date
- 2021-02-24
- Lead Sponsor
- Zambon SpA
- Target Recruit Count
- 24
- Registration Number
- NCT03881163
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, No.197 Ruijin Er Road, China
A Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa
- First Posted Date
- 2019-03-19
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Zambon SpA
- Target Recruit Count
- 307
- Registration Number
- NCT03881371
- Locations
- 🇨🇳
Beijing Tiantan Hospital Affiliated to Capital Medical University 首都医科大学附属北京天坛医院, Beijing, No. 6, Tiantan XI Li, Chongwen District, China
🇨🇳The First Bethune Hospital of Jilin University, Changchun, No. 71, Xin Min Street, China
🇨🇳The Second Affiliated Hospital of Zhejiang University 浙江大学医学院附属第二医院, Hangzhou, No. 88, Jie Fang Rd., China
A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus Secretions
- Conditions
- Respiratory Tract DiseasesAbnormal Mucus Secretions
- Interventions
- First Posted Date
- 2019-02-18
- Last Posted Date
- 2023-01-05
- Lead Sponsor
- Zambon SpA
- Target Recruit Count
- 333
- Registration Number
- NCT03843541
- Locations
- 🇨🇳
Suining Central Hospital, SuiNing, China
🇨🇳Wuxi Peoples' Hospital affiliated to Nanjing Medical University, Wuxi, China
🇨🇳Peking University Shougang Hospital, Beijing, China